Boehringer Ingelheim Vetmedica has launched a new injection-based antispasmodic treatment designed for use among horses and calves.
Buscopan 20mg/ml is being distributed via veterinary wholesalers and is specified as a therapy for equine colic, as well as acting as an aid to the symptomatic treatment of calf scour.
The drug is a sister product to Buscopan Compositum, which contains both an antispasmodic and a non-steroidal component.
Unlike the existing Buscopan offering, the new product contains only the antispasmodic component hyoscine butylbromide, thereby addressing an unmet demand from livestock owners.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica, said: "Our customers have been telling us for some time that they would really welcome a Buscopan formulation without a non-steroidal anti-inflammatory drug for use in horses and cattle."See all the latest jobs in Animal Health